Treatment
CDK4/6 inhibitor clinical trials
We’re tracking 49 recruiting studies that include CDK4/6 inhibitor, each written for real people, not researchers, below.
Recruiting studies
- NCT07652762RecruitingPhase 1
IN10018 and dalpiciclib for progressive meningioma
This trial tests a combination of two oral drugs, IN10018 and dalpiciclib, for people with progressive meningioma (a type of brain tumor) that has not responded to standard treatments. The goal is to see if this combination can help shrink or slow the tumor.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07581834RecruitingPhase 2
Dalpiciclib plus hormone therapy for early hormone-positive breast cancer
This study tests whether adding a new drug called dalpiciclib to standard hormone therapy improves outcomes for women with early-stage breast cancer that is hormone-receptor positive. The goal is to see if this combination is more effective and safe than hormone therapy alone.
Fuzhou, FujianAges 18 years+ - NCT06171360Recruiting
Gut bacteria and CDK4/6 inhibitor treatment in breast cancer
This study looks at how gut bacteria affect response to a type of targeted therapy (CDK4/6 inhibitors) combined with hormone therapy in breast cancer that is hormone receptor-positive and HER2-negative. It may help find out why some people respond better to treatment and could lead to better personalized care.
BrusselsAges 18–100 - NCT07491380Recruiting
Blood monitoring for breast cancer drugs at home
This study tests a finger-prick blood test you can do at home to check levels of your breast cancer medication (ribociclib, abemaciclib, or palbociclib). The goal is to make monitoring easier and more convenient.
ParisAges 18 years+ - NCT07432178RecruitingPhase 3
Targeted pill to skip chemo for high-risk breast cancer
This trial tests whether adding a targeted pill (dalpiciclib) to standard hormone therapy can safely replace chemotherapy for women with small, hormone-positive, high-risk breast cancers.
ShanghaiAges 18–70 - NCT07407439Recruiting
Real-world study of CDK4/6 inhibitors in advanced breast cancer
This study looks at how well CDK4/6 inhibitors (a type of targeted therapy) work in real-world patients with HR+/HER2- advanced breast cancer. By collecting medical data from people treated at this hospital, doctors hope to learn more about the effectiveness and safety of these drugs in everyday practice.
TianjinAges 18 years+ - NCT07399808Recruiting
CDK4/6 Inhibitors in Older Breast Cancer Patients
This study looks at how well CDK4/6 inhibitors work in older adults with breast cancer who are taking these drugs after surgery to help prevent the cancer from coming back. It will follow patients over time to learn more about their experiences.
Pavia, PaviaAges 18 years+ - NCT07273357Recruiting
CDK4/6 inhibitors for older breast cancer patients
This study looks at how well older breast cancer patients (70 years and older) do when treated with a type of drug called a CDK4/6 inhibitor along with hormone therapy after surgery. The goal is to use simple health checks to help doctors decide if this treatment is right for you.
GävleAges 70 years+ - NCT07258108RecruitingPhase 2
Sac-TMT and KL-A167 for HR+/HER2- Breast Cancer
This trial is testing a combination of two drugs, Sac-TMT and KL-A167, in people with a certain type of advanced breast cancer (HR+/HER2-) that is PD-L1 positive. It's for those whose cancer has gotten worse after treatment with a CDK4/6 inhibitor and hormone therapy.
Guangzhou, GuangdongAges 18–75 - NCT07214532Recruiting
Using a blood test to guide breast cancer therapy
This study tests whether a blood test can help decide when to start additional hormone-blocking therapy for early-stage breast cancer. It aims to see if starting therapy only when the test detects cancer DNA is as effective as giving it to everyone.
Phoenix, ArizonaAges 18 years+ - NCT07215364Recruiting
Exercise and quality of life in early breast cancer on hormone therapy
This trial tests if a supervised exercise program can improve quality of life for people with early-stage breast cancer who are currently taking hormone therapy (aromatase inhibitors with or without CDK4/6 inhibitors). It aims to see if exercise helps reduce side effects like fatigue and pain.
L'Hospitalet de Llobregat, BarcelonaAges 18 years+ - NCT07198724RecruitingPhase 1/Phase 2
A study of elacestrant plus Enhertu for advanced breast cancer
This trial tests a new combination of two targeted drugs (elacestrant and Enhertu) for people with a specific type of advanced breast cancer (HR-positive, HER2-low or ultra-low) that did not respond to standard treatments like CDK4/6 inhibitors. The goal is to see if this combination works better than current options.
Boston, MassachusettsAges 18 years+ - NCT07180160RecruitingPhase 2
A study of QL1706 for HR-positive, HER2-negative breast cancer
This trial tests a new drug combination (iparomlimab and tuvonralimab, also called QL1706) for people with advanced breast cancer that is hormone receptor-positive and HER2-negative. It may be an option if standard treatments have stopped working.
ShanghaiAges 18 years+ - NCT06959979RecruitingEarly Phase 1
Studying New Treatments for Medulloblastoma
This trial is studying the genetic details of medulloblastoma tumors in children to find new, targeted treatments. If your child had surgery for medulloblastoma at our pediatric center, their tumor tissue may help us learn more.
Roma, ROMAAges birth–18 years - NCT06790693RecruitingPhase 3
Inavolisib plus hormone therapy for advanced breast cancer
This trial tests a new targeted therapy, inavolisib, combined with standard hormone therapy and a CDK4/6 inhibitor for people with a specific genetic mutation (PIK3CA) in their hormone receptor-positive, HER2-negative advanced breast cancer that has not been treated before. It compares this combination to a placebo plus the same standard treatments.
Goodyear, ArizonaAges 18 years+ - NCT05181033RecruitingPhase 2
Lenvatinib plus letrozole versus fulvestrant for metastatic breast cancer
This Phase 2 study compares a combination medicine (lenvatinib plus letrozole) against fulvestrant to treat metastatic estrogen-receptor positive, HER2-negative breast cancer after the cancer has grown despite hormone therapy plus a CDK4/6 inhibitor. It may help by finding a more effective treatment option after your first lines have stopped working.
SingaporeAges 18–99 - NCT06650748Enrolling by invitationPhase 2
A study of hormone therapy with or without a targeted drug for breast cancer
This trial tests if adding a targeted drug (CDK4/6 inhibitor) to hormone therapy works better than hormone therapy alone for women with a certain type of breast cancer (HR+/HER2-). The study measures the activity of tumor cells (Ki-67) to help decide treatment.
BeijingAges 18–70 - NCT06481956Enrolling by invitationPhase 2
T-DM1 plus a CDK4/6 inhibitor (ribociclib) for HER2-positive breast cancer
This clinical trial tests a combination of two targeted therapies for people with HER2-positive breast cancer that has spread or come back. The goal is to see if adding ribociclib to T-DM1 is safe and effective after other treatments have been used.
Hangzhou, ZhejiangAges 18–75 - NCT06380751RecruitingPhase 3
New targeted therapy for BRCA/PALB2-mutated HR+ breast cancer
This trial tests a new combination of targeted therapies (saruparib plus camizestrant or hormone therapy) against standard treatments for people with a specific type of advanced breast cancer. It may be a good option if you have a BRCA1, BRCA2, or PALB2 gene mutation and have not yet had treatment for your advanced disease.
Gilbert, ArizonaAges 18 years+ - NCT06377852RecruitingPhase 3
CDK4/6 inhibitor dosing study for older adults with metastatic breast cancer
This study tests two targeted therapy drugs, palbociclib and ribociclib, combined with hormone therapy for people aged 60 or older with hormone receptor-positive, HER2-negative metastatic breast cancer. The goal is to see how well this treatment works and to gather information that may help improve dosing for older adults.
Chandler, ArizonaAges 60 years+ - NCT06062498RecruitingPhase 2
Elacestrant alone or with a CDK4/6 inhibitor for advanced breast cancer
This trial compares a new hormone therapy (elacestrant) to the same therapy combined with a CDK4/6 inhibitor (palbociclib, abemaciclib, or ribociclib) for people with a specific type of advanced breast cancer (ER-positive, HER2-negative) that has a mutation in the ESR1 gene. It aims to see if the combination works better than the single drug.
Chicago, IllinoisAges 18 years+ - NCT04526587Recruiting
Study of breast cancer markers after CDK4/6 inhibitor treatment
This study looks at lab markers and clinical features in people with certain types of breast cancer who are being treated with, or have already been treated with a CDK4/6 inhibitor like abemaciclib (ciclib-based therapy). It aims to understand patterns that may help doctors better characterize breast cancer after these treatments.
Buffalo, New YorkAges 18 years+ - NCT04660435Recruiting
Study how breast cancers resist CDK4/6 inhibitor treatment
This study looks at why some ER-positive, HER2-negative metastatic breast cancers don’t respond well to CDK4/6 inhibitors combined with hormone therapy. It may help researchers understand resistance and improve future treatment choices for people like you.
Prato, TuscanyAges Any age - NCT03310879RecruitingPhase 2
Abemaciclib for advanced tumors with cyclin or CDK4/6 gene changes
This Phase 2 study tests abemaciclib, a targeted cancer medicine, in people with advanced solid tumors that have specific gene changes related to cyclin D or CDK4/6. The goal is to see how well it controls tumors when standard treatments don’t work or aren’t available.
Boston, MassachusettsAges 18 years+
Common questions
- Are there clinical trials studying CDK4/6 inhibitor?
- Yes. Clin2 currently lists 49 recruiting studies that include CDK4/6 inhibitor, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a CDK4/6 inhibitor trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is CDK4/6 inhibitor an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether CDK4/6 inhibitor or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.